These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 32624537)

  • 21. RNA-Seq profiling reveals aberrant RNA splicing in patient with adult acute myeloid leukemia during treatment.
    Li XY; Yao X; Li SN; Suo AL; Ruan ZP; Liang X; Kong Y; Zhang WG; Yao Y
    Eur Rev Med Pharmacol Sci; 2014; 18(9):1426-33. PubMed ID: 24867525
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Towards understanding pre-mRNA splicing mechanisms and the role of SR proteins.
    Sahebi M; Hanafi MM; van Wijnen AJ; Azizi P; Abiri R; Ashkani S; Taheri S
    Gene; 2016 Aug; 587(2):107-19. PubMed ID: 27154819
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Aberrant expression of splicing factors in newly diagnosed acute myeloid leukemia.
    Liu J; Huang B; Xiao Y; Xiong HM; Li J; Feng DQ; Chen XM; Zhang HB; Wang XZ
    Onkologie; 2012; 35(6):335-40. PubMed ID: 22722453
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [A primer for epigenetics of hematological malignancies].
    Nakajima H
    Rinsho Ketsueki; 2016; 57(10):1835-1844. PubMed ID: 27725578
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Splicing factor mutations in hematologic malignancies.
    Chen S; Benbarche S; Abdel-Wahab O
    Blood; 2021 Aug; 138(8):599-612. PubMed ID: 34157091
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ribosomal protein pNO40 mediates nucleolar sequestration of SR family splicing factors and its overexpression impairs mRNA metabolism.
    Lin YM; Chu PH; Li YZ; Ouyang P
    Cell Signal; 2017 Apr; 32():12-23. PubMed ID: 28069438
    [TBL] [Abstract][Full Text] [Related]  

  • 27. SRSF2 Regulates Alternative Splicing to Drive Hepatocellular Carcinoma Development.
    Luo C; Cheng Y; Liu Y; Chen L; Liu L; Wei N; Xie Z; Wu W; Feng Y
    Cancer Res; 2017 Mar; 77(5):1168-1178. PubMed ID: 28082404
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Splice factor mutations and alternative splicing as drivers of hematopoietic malignancy.
    Hahn CN; Venugopal P; Scott HS; Hiwase DK
    Immunol Rev; 2015 Jan; 263(1):257-78. PubMed ID: 25510282
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development of a high-resolution melting curve analysis screening test for SRSF2 splicing factor gene mutations in myelodysplastic syndromes.
    Garza E; Fabiani E; Noguera N; Panetta P; Piredda ML; Borgia L; Maurillo L; Catalano G; Voso MT; Lo-Coco F
    J Mol Diagn; 2015 Jan; 17(1):85-9. PubMed ID: 25445211
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Aberrant RNA splicing and mutations in spliceosome complex in acute myeloid leukemia.
    Zhou J; Chng WJ
    Stem Cell Investig; 2017; 4():6. PubMed ID: 28217708
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [The epigenetic effect on pre-mRNA alternative splicing].
    Zhao J; Wang F; Xu Z; Fan Y
    Yi Chuan; 2014 Mar; 36(3):248-55. PubMed ID: 24846965
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cancer-Associated Perturbations in Alternative Pre-messenger RNA Splicing.
    Shkreta L; Bell B; Revil T; Venables JP; Prinos P; Elela SA; Chabot B
    Cancer Treat Res; 2013; 158():41-94. PubMed ID: 24222354
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The prognostic impact of mutations in spliceosomal genes for myelodysplastic syndrome patients without ring sideroblasts.
    Kang MG; Kim HR; Seo BY; Lee JH; Choi SY; Kim SH; Shin JH; Suh SP; Ahn JS; Shin MG
    BMC Cancer; 2015 Jun; 15():484. PubMed ID: 26115659
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Epigenetic regulation in human melanoma: past and future.
    Sarkar D; Leung EY; Baguley BC; Finlay GJ; Askarian-Amiri ME
    Epigenetics; 2015; 10(2):103-21. PubMed ID: 25587943
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel working hypothesis for pathogenesis of hematological malignancies: combination of mutations-induced cellular phenotypes determines the disease (cMIP-DD).
    Kitamura T; Watanabe-Okochi N; Enomoto Y; Nakahara F; Oki T; Komeno Y; Kato N; Doki N; Uchida T; Kagiyama Y; Togami K; Kawabata KC; Nishimura K; Hayashi Y; Nagase R; Saika M; Fukushima T; Asada S; Fujino T; Izawa Y; Horikawa S; Fukuyama T; Tanaka Y; Ono R; Goyama S; Nosaka T; Kitaura J; Inoue D
    J Biochem; 2016 Jan; 159(1):17-25. PubMed ID: 26590301
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular Pathways: Understanding and Targeting Mutant Spliceosomal Proteins.
    Yoshimi A; Abdel-Wahab O
    Clin Cancer Res; 2017 Jan; 23(2):336-341. PubMed ID: 27836865
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Epigenetic therapy for hematologic malignancies].
    Kobayashi Y
    Rinsho Ketsueki; 2015 Oct; 56(10):2015-23. PubMed ID: 26458440
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of Splicing Factor Mutations on Pre-mRNA Splicing in the Myelodysplastic Syndromes.
    Yip BH; Dolatshad H; Roy S; Pellagatti A; Boultwood J
    Curr Pharm Des; 2016; 22(16):2333-44. PubMed ID: 26916023
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Splicing factor gene mutations in hematologic malignancies.
    Saez B; Walter MJ; Graubert TA
    Blood; 2017 Mar; 129(10):1260-1269. PubMed ID: 27940478
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characterization of disease-associated mutations affecting an exonic splicing enhancer and two cryptic splice sites in exon 13 of the cystic fibrosis transmembrane conductance regulator gene.
    Aznarez I; Chan EM; Zielenski J; Blencowe BJ; Tsui LC
    Hum Mol Genet; 2003 Aug; 12(16):2031-40. PubMed ID: 12913074
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.